Skin Sights from Winter Clinical Miami 2026: Key Dermatology Advances with Wound Care Relevance
Summary: Dermatology Times published a LinkedIn roundup of clinical highlights from the 2026 Winter Clinical Miami Dermatology Conference, held February 27–March 1 at the JW Marriott Miami Turnberry in Aventura, Florida. The three-day CME conference convened leading dermatologists for comprehensive updates across medical, surgical, and cosmetic dermatology. Sessions of particular relevance to wound care practitioners included content on inflammatory skin disease — including advances in biologics targeting IL-17, IL-23, and IL-4/13 pathways that intersect with skin barrier dysfunction and chronic wound inflammation — as well as melanoma diagnostics, acne and rosacea management, and emerging AI-driven practice tools. Mark Lebwohl, MD, presented advances in psoriasis including the investigational oral peptide icotrokinra and a new extended-release formulation of apremilast, while multiple sessions addressed atopic dermatitis pipeline progress, including new biologics and JAK inhibitors. The meeting also featured a session on pediatric dermatology, skin of color, and a 20-tips-in-20-minutes rapid-fire clinical pearls panel integrating practice management, off-label treatment considerations, and AI-driven operational strategies. A separate track for early-career dermatologists addressed contract negotiation, ethical industry collaboration, and workflow optimization. The LinkedIn article, produced by Dermatology Times, aggregates key takeaways relevant to dermatology and skin care practice from across the full conference program.
Key Highlights:
- Conference dates: February 27–March 1, 2026 | Location: JW Marriott Miami Turnberry, Aventura, Florida
- Psoriasis advances: icotrokinra (investigational oral peptide) and 75-mg extended-release apremilast — expanding the oral treatment landscape for inflammatory skin disease
- Atopic dermatitis pipeline: new biologics and JAK inhibitors discussed alongside IL-23 inhibition advances with tildrakizumab real-world Medicare durability data
- AI in practice: tools for EMR-based patient recall, aesthetic scheduling, and operational revenue generation — directly applicable to wound care clinic management
- Pediatric focus: Lisa Swanson, MD, shared prior-authorization-free treatment strategies and called for expanded research inclusion for children under 12
- Wound care relevance: advances in skin barrier biology, biologic immunology, and anti-inflammatory pathway targeting have direct implications for chronic wound pathophysiology and management
Keywords: dermatology conference 2026, skin inflammation wound, biologics skin disease, atopic dermatitis, psoriasis wound care, Winter Clinical Miami
Dermatology Times Editorial Team